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Thirty years ago the now 
Nobel Prize winner 
Harald Zur Hausen first 
described high-risk human 
papillomavirus (hrHPV) 
type 16 in cervical cancer specimens 
(Fig. 1). Since then, hrHPV infection has 
been established as a prerequisite for the 
development of cervical cancer. Cervical 
cancer prevention programmes in many 
developed countries already include 
primary prevention through immunisation 
against hrHPV types 16 and 18 before 
hrHPV exposure, combined with secondary 
prevention via cytology-based screening, 
often augmented by testing for hrHPV 
infection. The benefit of acquired knowledge 
and new technologies must now be extended 
to developing countries, where 85% of deaths 
attributable to cervical cancer occur.
In South Africa (SA) the prevalence of 
this preventable cancer is alarmingly high, 
presentation is late and survival rates are 
poor, in spite of excellent treatment available 
at most tertiary facilities. The unfortunate 
underlying reasons include opportunistic 
and variably implemented cytology-based 
screening,[1] and a poorly controlled human 
immunodeficiency virus (HIV) epidemic 
with high HIV prevalence, late diagnosis and 
incomplete access to timely treatment. The 
effect of HIV co-infection on the prevalence 
and natural history of HPV infection and 
associated disease is well described in the 
literature[2] and seen by gynaecological 
oncologists in SA (Fig. 2).
Cervical cancer and infectious disease 
experts in SA have discussed the causes of 
and potential solutions to this epidemic 
for several years. After consideration of the 
available evidence, a group of local experts 
published guidelines for the implementation 
of primary screening with hrHPV testing 
in 2005, with an update in 2010.[3] These 
guidelines were among the first in the world 
to acknowledge the potential of hrHPV 
molecular tests in primary screening, 
and also proposed self-sampling. An 
hrHPV-based screening cost-effectiveness 
analysis[4] and clinical guidelines for HPV 
vaccine implementation in SA were also 
published.[5] Unfortunately, uptake of HPV 
vaccination has been slow[6] and population-
based screening remains only partially 
implemented.[1]
In this issue of SAMJ, Moodley et al. report 
the outcome of a vaccine demonstration 
project in rural KwaZulu-Natal (KZN).[7] 
Almost all the girls who had parental consent 
and therefore met the inclusion criteria 
received the first dose of vaccine, and the 
completion rate of 97.8% was impressive. It 
is important to demonstrate effective vaccine 
delivery in SA schools, and these results will 
assist in planning larger vaccine projects. 
Among the lessons learnt, the authors 
mention various aspects of administration 
and training, communication and team 
involvement. The authors, co-workers 
and sponsors must be commended for the 
huge effort and successful completion of 
this trial. To reach a high uptake in this 
study, information and motivation of all 
stakeholders and proper communication 
with schools, teachers, parents, girls and 
their communities were ensured and were 
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Fig. 2. Age at presentation of women with invasive cervical cancer (unpublished data, University of 
Pretoria Gynaecological Oncology Unit, 2011).
1928          Georgios Papanicolaou developed the Papanicolaou technique
1941          First ‘Pap smear’ screening technique developed
1949          First mass ‘Pap smear’ screening
1949          HPV seen on an electron microscope
1963          HPV DNA identied
1976          Harald Zur Hausen found HPV DNA in cervical cancer and warts
1983          Harald Zur Hausen identies HPV type 16 in cervical cancer
1984          Harald Zur Hausen identies HPV type 18 in cervical cancer
1988          Bethesda System for reporting ‘Pap smear’ results developed
2003          First HPV-based cervical cancer screening test FDA approved
2006          First HPV vaccine, Gardasil (Merck), approved by the FDA
2007          Second HPV vaccine, Cervarix (GSK), approved by the FDA
2008          Gardasil and Cervarix approved by the MCC in South Africa
Fig. 1. The history of cervical cancer prevention and human papillomavirus (FDA = US Food and Drug 
Administration; MCC = Medicines Control Council).
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thought to be critical. Apart from the uptake of the vaccine, cost-
effectiveness of a national HPV vaccination programme will be 
determined by the burden of disease, vaccine pricing, number of 
doses administered, viral types covered (both vaccine types and 
cross-protection), and cost of the vaccination process.
The hrHPV prevalence among a large sample of SA women reported 
by Richter et al. in this issue of SAMJ is cause for alarm, although 
these results cannot be generalised to all women in sub-Saharan 
Africa.[8] This study, performed among women attending public sector 
primary healthcare clinics in the Tshwane area of Gauteng, describes 
the highest prevalence of hrHPV ever reported in an unselected 
screening population (Fig. 3). Importantly, the age distribution shows 
a unique plateau-like curve without the expected decline of HPV 
infection from age 30 and older. The risk factors associated with 
increased HPV infection rates were not studied in this trial, but are 
well known.[2,9] In addition, the reported prevalence of high-grade 
intraepithelial lesions (HSIL) or worse on cytology is near 10%. This 
unprecedented high prevalence on a single round of cytology testing 
correlates with extremely high prevalences of HPV types 16 and/or 
18 (near 20%) and hrHPV overall (over 50%), as well as with the high 
prevalence and young age at presentation of women with invasive 
cervical cancer. Cervical cancer is the leading cause of cancer death in 
women in southern Africa, despite being one of the most preventable 
of all malignancies. The high burden of disease demonstrated in this 
study underlines the importance and urgency of HPV vaccination and 
screening in SA, and indicates a high expected return on investment.
Implementing HPV vaccination. Although too late for women who 
are already infected, the commercial launch of two vaccines against 
HPV in 2006 and 2007 meant that future generations of women can go 
into their sexually active years protected from HPV types 16 and 18, 
which cause 60 - 70% of cervical cancers. Remaining hurdles include 
the cost and complexity of the implementation process. Vaccination 
systems that can ensure a high uptake and deliver all doses within a 
6-month period in a school-based programme are needed. Effective 
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Fig. 3. Age-related prevalence of human papillomavirus infections, 
(squares), pre-cancerous lesions (triangles), and cervical cancer (circles) 
as traditionally described in the developed world (solid lines)[9] and in the 
general South African population (dashed lines), as described by Richter et 
al.[8] and unpublished data from the University of Pretoria Gynaecological 
Oncology Unit (2011). Th e fi gure shows trends and prevalence relative to 
each other rather than the absolute prevalence, so there is no vertical axis.
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Fig. 4. Cervical cancer prevention strategies in diﬀ erent patient populations. Current or proposed screening options integrating cytology, HPV testing, visual 
inspection and HPV vaccination in high-resourced,[12, 14] middle-resourced and low-resourced settings[15-17] are displayed (SA = South Africa; HPV = human 
papillomavirus; V = HPV vaccination; C = cytology-based screening; H = hrHPV-based screening; c = cytology-based screening if not previously screened; 
h = hrHPV-based screening if not previously screened; VI = visual inspection-based screening). 
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vaccine delivery with high uptake in the school setting has been 
demonstrated in KZN, Gauteng and the Western Cape.[7,10,11]
Implementing HPV-based screening. Mortality from cervical 
cancer in developed countries is low because of the availability of 
prevention by early detection of risk, followed by effective treatment. 
These successes have never been mirrored in the developing world. 
Cervical cancer mortality can be substantially lowered with any 
screening test, provided that the necessary coverage, screening 
interval, follow-up and treatment of screen-positive individuals can 
be guaranteed. The cost-effectiveness, sensitivity and specificity of 
the different tests and screening intervals are, however, very different. 
HrHPV-based screening tests offer several advantages over cytology-
based tests. These include increased clinical sensitivity and excellent 
negative predictive value. Screening intervals can therefore safely 
be increased. Women can self-collect samples, which will relieve 
healthcare personnel. Although evaluating this was not the primary 
aim of the study by Richter et al., willingness of women to self-collect 
in a subset of the study population is encouraging. HPV-based tests 
are also amenable to high-throughput automated laboratory testing 
as opposed to labour-intensive manual cytology screening.
Proposed cervical cancer prevention model for South Africa. 
The question arises: what is the optimal cervical cancer prevention 
programme for a middle-resourced country with an extremely high 
burden of HPV-associated disease like SA? Owing to limited resources, 
we cannot afford a ‘catch-all’ strategy and will have to optimise the 
cost-effectiveness of the preventive programme. Different cervical 
cancer prevention strategies and the proposed model for SA are 
outlined in Fig. 4. An ideal cervical cancer control programme 
should emphasise HPV vaccination before average age at first sexual 
intercourse, combined with appropriately spaced hrHPV testing for 
primary screening, starting at age 30 years in immunocompetent 
women (option C).[12] Vaccine coverage must first be directed where 
it will have the greatest impact. Although the case can be made for 
catch-up vaccination of adult women, and boys, the initial target 
should therefore be girls before their sexual debut. It is widely accepted 
that HPV vaccination should be primary school based.
Universal vaccination of young girls is only expected to start to 
result in a decrease in cervical cancer incidence after two decades. 
Screening will remain essential for unvaccinated women and to 
screen for cancers caused by non-vaccine types in vaccinated women. 
Modern assays provide good choices for lower-resourced settings 
with a high HPV prevalence, enabling prioritisation of women at 
highest risk of cancer while maintaining the excellent sensitivity 
that allows a longer screening interval. While earlier hrHPV DNA-
based tests needed an additional triage test to improve specificity 
and predictive value, newer tests are designed for screening and 
combine high sensitivity with increased clinical specificity. This is 
accomplished by partial hrHPV DNA genotyping and calibration 
against risk for clinically relevant disease, or by type-specific testing 
for mRNA expression of the HPV oncogenes E6 and E7.[13,14]
Experts agree that the current emphasis on repeated cytology 
screening as in established programmes (option A) is inefficient. 
Most new proposals call for less frequent but more sensitive screening 
that incorporates testing for hrHPV.[12,14] For developed settings, 
co-testing has been proposed (option B),[12,14] but such a strategy is 
highly resource intensive and reflects fear of litigation. In contrast, 
the World Health Organization suggests a minimum of screening at 
least a once in a lifetime between the ages of 35 and 45 years for the 
lowest-resourced settings (option F).[15] This screening can be visual 
inspection based (lowest accuracy), cytology based (low sensitivity) or 
HPV based (high sensitivity), as demonstrated in India[16] and in SA.[17]
We propose initiation of primary school-based HPV vaccination as 
soon as possible, as well as 10-yearly HPV-based screening (option E), 
combined with effective treatment of women with positive screening 
tests. This strategy will provide a major advancement in cervical 
cancer prevention when compared with the current inefficient 
cytology guidelines for SA (option D). Vaccination and screening 
programmes should focus on the least-serviced communities first. 
HPV vaccination and adequately implemented hrHPV-based 
screening in SA can save the lives of many women.
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